Search research articles
Contact Us
Filters
Showing results (111-120 of 116) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 116 results.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
March 22, 2020
Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC)
A Villers, F Bessaoud, B Trétarre, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
November 7, 2015
[Not Available]
A Gryn, B Duly-Bouhanick, A Bennet, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
October 14, 2015
[Not Available]
A Gryn, J Gas, M Thoulouzan, et al.
World Journal of Urology
|
April 22, 2024
The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology
G Sorce, A Stabile, F Pellegrino, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
October 14, 2015
[Not Available]
T Murez, X Durand, M Rivoire, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
A Kramar, S Negrier, R Sylvester, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 116) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 116 results.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
March 22, 2020
Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC)
A Villers, F Bessaoud, B Trétarre, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
November 7, 2015
[Not Available]
A Gryn, B Duly-Bouhanick, A Bennet, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
October 14, 2015
[Not Available]
A Gryn, J Gas, M Thoulouzan, et al.
World Journal of Urology
|
April 22, 2024
The impact of mpMRI-targeted vs systematic biopsy on the risk of prostate cancer downgrading at final pathology
G Sorce, A Stabile, F Pellegrino, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|
October 14, 2015
[Not Available]
T Murez, X Durand, M Rivoire, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†
A Kramar, S Negrier, R Sylvester, et al.
Page
of 12